These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8376682)

  • 21. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
    Mager G; Klocke RK; Kux A; Höpp HW; Hilger HH
    Am Heart J; 1991 Jun; 121(6 Pt 2):1974-83. PubMed ID: 1852090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside].
    Domínguez de Rozas JM; Guindo Soldevila J; Rodríguez Font E; Martínez Vílchez R
    Rev Esp Cardiol; 1994 Oct; 47(10):682-6. PubMed ID: 7991922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure.
    Ribeiro JP; White HD; Arnold JM; Hartley LH; Colucci WS
    Am J Med; 1986 Nov; 81(5):759-64. PubMed ID: 3535490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of chronic heart failure with digitalis: are there still indications?].
    Strasser RH
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S32-6. PubMed ID: 10535044
    [No Abstract]   [Full Text] [Related]  

  • 25. [New knowledge on the subject of therapy in cardiac decompensation in the light of large trials].
    Camerini F; Perkan A; Sinagra G; Di Lenarda A; Pinamonti B; Zecchin M
    Ann Ital Med Int; 1994 Oct; 9 Suppl():68S-77S. PubMed ID: 7857761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous milrinone in patients with severe congestive cardiac failure awaiting heart transplantation.
    Skoyles JR; Sherry KM; Price C
    J Cardiothorac Vasc Anesth; 1992 Apr; 6(2):222-5. PubMed ID: 1568013
    [No Abstract]   [Full Text] [Related]  

  • 27. [Response to milrinone treatment in patients with chronic congestive heart failure].
    Zeng H; Wen S; Huang D; Liu X; Fang Y
    Hua Xi Yi Ke Da Xue Xue Bao; 2000 Jun; 31(2):246-7, 259. PubMed ID: 12515150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
    Dickstein K; Chang P; Willenheimer R; Haunsø S; Remes J; Hall C; Kjekshus J
    J Am Coll Cardiol; 1995 Aug; 26(2):438-45. PubMed ID: 7608448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure.
    Böhm M; Deutsch HJ; Hartmann D; Rosée KL; Stäblein A
    J Am Coll Cardiol; 1997 Oct; 30(4):992-6. PubMed ID: 9316529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug therapy of congestive heart failure].
    Sasayama S
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1770-7. PubMed ID: 9410998
    [No Abstract]   [Full Text] [Related]  

  • 31. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
    Mehra MR; Ventura HO; Kapoor C; Stapleton DD; Zimmerman D; Smart FW
    Am J Cardiol; 1997 Jul; 80(1):61-4. PubMed ID: 9205021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Milrinone in the treatment of low output states following cardiac surgery.
    Wright EM; Skoyles J; Sherry KM
    Eur J Anaesthesiol Suppl; 1992; 5():21-6. PubMed ID: 1600964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the treatment of chronic heart failure.
    Poole-Wilson PA; Lindsay D
    BMJ; 1992 Apr; 304(6834):1069-70. PubMed ID: 1586817
    [No Abstract]   [Full Text] [Related]  

  • 35. Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure.
    White HD; Ribeiro JP; Hartley LH; Colucci WS
    Am J Cardiol; 1985 Jul; 56(1):93-8. PubMed ID: 4014048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure.
    Binkley PF; Haas GJ; Starling RC; Nunziata E; Hatton PA; Leier CV; Cody RJ
    J Am Coll Cardiol; 1993 Mar; 21(3):655-61. PubMed ID: 8436747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous milrinone in treatment of advanced congestive heart failure.
    Zewail AM; Nawar M; Vrtovec B; Eastwood C; Kar MN; Delgado RM
    Tex Heart Inst J; 2003; 30(2):109-13. PubMed ID: 12809251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of converting enzyme inhibitors in the treatment of heart failure.
    Hood WB
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):154A-157A. PubMed ID: 8376687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity.
    Narang R; Swedberg K; Cleland JG
    Eur Heart J; 1996 Jan; 17(1):120-34. PubMed ID: 8682118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition.
    Newby DE; McDonagh T; Currie PF; Northridge DB; Boon NA; Dargie HJ
    Eur Heart J; 1998 Dec; 19(12):1808-13. PubMed ID: 9886723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.